Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dew, if higher GT1 sales for Gilead is bearish for Enanta, I am not clear how analysts can revise sales and share upward for ABBV ? Could initial trejectory not representative of steady state for years to come for both Gilead and ABBV ? T.I.A
If he sells now than it becomes an issue.
Didn't Citi upgraded MDVN today ? PT 124
Do you see odds of B/O of ENTA go up after today' de-risk event ? T.I.A
Take it easy don't hurt yourself
Bullish for Tekmira and Arrowhead
GMO is increasingly becoming like a global warming debate. Proponents of GMO see little chance of feeding the growing masses especially in draught prone areas without such efforts. Regardless 'jack & the Bean stalk' reality is long way off.
During midday trading, ENTA was affected by Morgan Stanley’s new downgrade of ABBV and the lowering of its forecast for ABBV/ENTA’s HCV sales. The purported rationale for MS’s downgrade was the statement by ABBV’s CEO during the JPM webcast two weeks ago that ABBV did not need to compete with GILD on price.
When I heard ABBV’s JPM comment in real time, I thought it was modestly bullish for ENTA insofar as the thinly-veiled message was that ABBV/ENTA’s HCV regimen was strong enough to compete with GILD on efficacy and safety…period.
I still expect ABBV to price the 3-DAA regimen at a discount to GILD’s Sovaldi + Ledipasvir, but ABBV’s statement at JPM suggests that the discount will not be enormous and will not trigger a pricing war.
Good point. Still I bet there may be few nervous short term traders who might have a stop loss ~30 to trigger quick bounce..counting on it to add more !
I see it going over $20 at least by end if the year great if you are long term with lower tax
Thank for posting this info.
Great vote of confidence, IMO
Tekmira and Monsanto collaboration agreement
http://finance.yahoo.com/news/tekmira-signs-development-agreement-delivery-121500566.html
Tekmira and Arrowhead might be next. Possible further consolidation ?
Could this be a factor much as it would seem remote (ENTA is not exactly reducing from 50 to 5) ? Article recommends a size of 5 being optimal.
http://www.asaecenter.org/Resources/ANowDetail.cfm?ItemNumber=57713
Nevertheless, the reduction in BoD size (from 7 to 5) makes this an unusual and intriguing case. The people who presume that the BoD machinations stem from a disagreement regarding a buyout offer have to explain why the two vacated seats are not being filled.
Usually companies that reward at these astronomical scale to select few better cross every t and dot every i. Reason being 'not so well compensated' employees could turn out to be whistleblowers.
I believe they have $36 as target as well
Your reference to unrelated article is as stupid as it goes..lol
Absolutely. Market economics will win as price will be still high for patients to pay for themselves for choosing convenience.
FWIW, I think $ABBV/$ENTA will get their fair share by competing on price & marketing.
Agree as well. BTW do we know the % of prior null responders on GILD results ? For Enanta I saw from Dew's post it is 49% which is a high bar
IMUC ICT-107 --->>> FAIL period. It doesn't matter how you slice and dice, IMUC platform has no value now.
No wonder institutions were not loading up and insiders were flipping options like burgers including one of the directors recently unloaded a boatload of options above 3.
Mayo Clinic PR was a scam in disguise to entice retail to push stock pps higher. I bet they know the results when that PR was released but hard to prove.
I won't be surprised if law suits start flying..
I am glad I sold my 5k just below 3 when it started slipping week ago..
Dr. Singh's 1 M shares are now worth less than a toilet roll..ouch
Well said. Case in point recently is acquisition of TSRX by Cubist Pharma. All cash transaction even before NDA filing !
Just listen to recent CC. Very positive with potential partner possibility for Europe. Odds of Zalviso approval is high but one has to be patient
I actually glad it's sliding as I plan to add sizable chunk for my long term portfolio. The Perspective investors are no idiots or losers.
He is a clown and has no idea on the science or trial results. It's for a reason GILD insiders are selling in troves. Once the results come out for Pearl study that has arms without ribavirin we will see $45.
He never said to 'cut in half'. Just ring the cash register to take some off the table. He did say both ENTA & GILD has upside on his response.
Pretty Depressed & Friggin Upset
Agree. Possible harbinger of good news on Pearl study that has arms without Ribavirin, perhaps ?
It was Bioventure capital and VC typically scale down. If you carefully look the sold position if a small % of their entire ENTA holdings.
We will cross $10 easy upon FDA acceptance of their NDA PR..
What kind of DCF are they (Leerlink) using ? $29 target seem to be low unless prior to rest of P3 results (5 I believe). T.I.A
Also any mention on market share ?
Lol. And all are 'investors' looking for free ride
Agree. May be it will be an opportunity to get in cheaper
Actually I bought 5K at open today (2.65 avg) and sold AH today. Retaining my original 5K. I had once 40K but did not want to risk it all.
Anyway, I wish all the best for the pts but may be we all win in the end. But is it worth investing more than one can afford to lose ? Emphatically no, IMHO.
All said, next 3 months will be interesting.
AF factor has high influence and he has been known to be wrong. More recently VNDA which he blamed on FDA for various reasons..lol
Brian Nichols who is a perma bull on IMUC is very optimistic to a point he sees ICT-107 will get approved but the Q is when.
I suspect AF is coming out with a Street.com article soon, as he has been asked too many Q's on Sinai paper.
While I don't intend to sell into this rally yet, I am not adding either until dust settles. The actual PII results unlikely to come by end of this year. So will give plenty of time to add with overall market moves. Just IMO
Agree. However we have to keep in mind that all of the patients underwent resection..meaning part or whole of tumor were removed.
But definitely intriguing to say the least.
It is especially when it is not even global. At a minimum they should PR 64th event
Hope you are right. I still believe in science but still very wary about 4 to 4 months duration for data analysis which in all likelihood must have already started.
For any new investors I want to sound a word of caution. Do not invest more than you can lose.
Insiders do not appear to have any confidence on their own science. They are flipping their penny options like burgers when they could have waited few more months. Maxim is pathetic in defending these insider sales.
Disclaimer: I now view my 5k holding as a pure lotto ticket willing to lose it all.